遗传多态性对埃及 2 型糖尿病患者磺脲类药物继发性失效发展的影响。
Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.
机构信息
Faculty of Pharmacy, Tanta University, Egypt.
出版信息
Ther Adv Endocrinol Metab. 2011 Aug;2(4):155-64. doi: 10.1177/2042018811415985.
OBJECTIVE
This study investigated the possibility that genetic factors, such as polymorphism of K inward rectifier subunit (Kir6.2), E23K, and Arg(972) polymorphism of insulin receptor sub-strate-1 (IRS-1), may predispose patients to sulfonylurea failure.
METHODS
A total of 100 unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two equal groups: group I consisted of patients with secondary failure to sulfonylurea (hemoglobin A(1c) ≥ 8% despite sulfonylurea therapy) while group II consisted of patients whose condition was controlled with oral therapy.
RESULTS
Of all the patients, 45% and 14% were carriers of the K allele and Arg(972) variants respectively. The frequency of the K allele was 34% among patients with diabetes that was controlled with oral therapy and 56% among patients with secondary failure to sulfonylurea. The frequency of the Arg(972) IRS-1 variant was 6% among patients with diabetes controlled with oral therapy and 22% among patients with secondary failure.
CONCLUSION
The E23K variant of the Kir6.2 gene and Arg(972) IRS-1 variants are associated with increased risk for secondary failure to sulfonylurea.
目的
本研究旨在探讨遗传因素（如内向整流钾通道 6.2 亚基（Kir6.2）E23K 多态性和胰岛素受体底物-1（IRS-1）Arg972 多态性）是否可能导致患者磺酰脲类药物治疗失败。
方法
共招募了 100 例无亲缘关系的埃及 2 型糖尿病患者，将其分为两组：磺酰脲类药物继发失效组（HbA1c≥8%，尽管接受磺酰脲类药物治疗）和磺酰脲类药物控制组（口服药物治疗控制良好），每组各 50 例。
结果
所有患者中，K 等位基因和 Arg972 变异的携带者分别占 45%和 14%。磺酰脲类药物控制良好的患者中 K 等位基因的频率为 34%，磺酰脲类药物继发失效的患者中 K 等位基因的频率为 56%。IRS-1 中的 Arg972 变异在口服药物治疗控制良好的患者中占 6%，在磺酰脲类药物继发失效的患者中占 22%。
结论
Kir6.2 基因的 E23K 变异和 IRS-1 的 Arg972 变异与磺酰脲类药物继发失效风险增加相关。
Zotero 插件